Loading
A phase 3 trial of Sacituzumab tirumotecan, Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., active and no longer recruiting.
A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06670196 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 420 participants planned, started 2024-11-27 and due to reach its primary completion in 2027-05. Interventions recorded: SKB264, Osimertinib. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Osimertinib, EGFR-mutated non-small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Osimertinib, Small-cell lung cancer.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.